Maryam Ehsasatvatan1, Bahram Baghban Kohnehrouz2, Ashraf Gholizadeh3, Hamideh Ofoghi4, Dariush Shanehbandi5. 1. Department of Plant Breeding & Biotechnology, Faculty of Agriculture, University of Tabriz, 51666, Tabriz, Iran. 2. Department of Plant Breeding & Biotechnology, Faculty of Agriculture, University of Tabriz, 51666, Tabriz, Iran. bahramrouz@yahoo.com. 3. Department of Animal Biology, Faculty of Natural Science, University of Tabriz, 51666, Tabriz, Iran. 4. Department of Biotechnology, Iranian Research Organization for Science and Technology (IROST), 33131, Tehran, Iran. 5. Immunology Research Center, Tabriz University of Medical Sciences, 51666, Tabriz, Iran.
Abstract
BACKGROUND: Designed mimetic molecules are attractive tools in biopharmaceuticals and synthetic biology. They require mass and functional production for the assessment of upcoming challenges in the near future. The DARPin family is considered a mimetic pharmaceutical peptide group with high affinity binding to specific targets. DARPin G3 is designed to bind to the HER2 (human epidermal growth factor receptor 2) tyrosine kinase receptor. Overexpression of HER2 is common in some cancers, including breast cancer, and can be used as a prognostic and predictive tool for cancer. The chloroplasts are cost-effective alternatives, equal to, and sometimes better than, bacterial, yeast, or mammalian expression systems. This research examined the possibility of the production of the first antibody mimetic, DARPin G3, in tobacco chloroplasts for HER2 imaging in oncology. RESULTS: The chloroplast specific DARPin G3 expression cassette was constructed and transformed into N. tabacum chloroplasts. PCR and Southern blot analysis confirmed integration of transgenes as well as chloroplastic and cellular homoplasmy. The Western blot analysis and ELISA confirmed the production of DARPin G3 at the commercial scale and high dose with the rate of 20.2% in leaf TSP and 33.7% in chloroplast TSP. The functional analysis by ELISA confirmed the binding of IMAC purified chloroplast-made DARPin G3 to the extracellular domain of the HER2 receptor with highly effective picomolar affinities. The carcinoma cellular studies by flow cytometry and immunofluorescence microscopy confirmed the correct functioning by the specific binding of the chloroplast-made DARPin G3 to the HER2 receptor on the surface of HER2-positive cancer cell lines. CONCLUSION: The efficient functional bioactive production of DARPin G3 in chloroplasts led us to introduce plant chloroplasts as the site of efficient production of the first antibody mimetic molecules. This report, as the first case of the cost-effective production of mimetic molecules, enables researchers in pharmaceuticals, synthetic biology, and bio-molecular engineering to develop tool boxes by producing new molecular substitutes for diverse purposes.
BACKGROUND: Designed mimetic molecules are attractive tools in biopharmaceuticals and synthetic biology. They require mass and functional production for the assessment of upcoming challenges in the near future. The DARPin family is considered a mimetic pharmaceutical peptide group with high affinity binding to specific targets. DARPin G3 is designed to bind to the HER2 (human epidermal growth factor receptor 2) tyrosine kinase receptor. Overexpression of HER2 is common in some cancers, including breast cancer, and can be used as a prognostic and predictive tool for cancer. The chloroplasts are cost-effective alternatives, equal to, and sometimes better than, bacterial, yeast, or mammalian expression systems. This research examined the possibility of the production of the first antibody mimetic, DARPin G3, in tobacco chloroplasts for HER2 imaging in oncology. RESULTS: The chloroplast specific DARPin G3 expression cassette was constructed and transformed into N. tabacum chloroplasts. PCR and Southern blot analysis confirmed integration of transgenes as well as chloroplastic and cellular homoplasmy. The Western blot analysis and ELISA confirmed the production of DARPin G3 at the commercial scale and high dose with the rate of 20.2% in leaf TSP and 33.7% in chloroplast TSP. The functional analysis by ELISA confirmed the binding of IMAC purified chloroplast-made DARPin G3 to the extracellular domain of the HER2 receptor with highly effective picomolar affinities. The carcinoma cellular studies by flow cytometry and immunofluorescence microscopy confirmed the correct functioning by the specific binding of the chloroplast-made DARPin G3 to the HER2 receptor on the surface of HER2-positive cancer cell lines. CONCLUSION: The efficient functional bioactive production of DARPin G3 in chloroplasts led us to introduce plant chloroplasts as the site of efficient production of the first antibody mimetic molecules. This report, as the first case of the cost-effective production of mimetic molecules, enables researchers in pharmaceuticals, synthetic biology, and bio-molecular engineering to develop tool boxes by producing new molecular substitutes for diverse purposes.
Authors: Ulla Wilking; Eva Karlsson; Lambert Skoog; Thomas Hatschek; Elisabet Lidbrink; Goran Elmberger; Hemming Johansson; Linda Lindström; Jonas Bergh Journal: Breast Cancer Res Treat Date: 2010-07-14 Impact factor: 4.872
Authors: E C Dijkers; T H Oude Munnink; J G Kosterink; A H Brouwers; P L Jager; J R de Jong; G A van Dongen; C P Schröder; M N Lub-de Hooge; E G de Vries Journal: Clin Pharmacol Ther Date: 2010-03-31 Impact factor: 6.875
Authors: Nehmat Houssami; Petra Macaskill; Rosemary L Balleine; Michael Bilous; Mark D Pegram Journal: Breast Cancer Res Treat Date: 2011-06-23 Impact factor: 4.872
Authors: Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett Journal: Arch Pathol Lab Med Date: 2018-05-30 Impact factor: 5.686
Authors: Edward Gitau Mathenge; Cheryl Ann Dean; Derek Clements; Ahmad Vaghar-Kashani; Steffany Photopoulos; Krysta Mila Coyle; Michael Giacomantonio; Benjamin Malueth; Anna Nunokawa; Julie Jordan; John D Lewis; Shashi Ashok Gujar; Paola Marcato; Patrick W K Lee; Carman Anthony Giacomantonio Journal: Neoplasia Date: 2014-11-20 Impact factor: 5.715
Authors: G Gebhart; L E Lamberts; Z Wimana; C Garcia; P Emonts; L Ameye; S Stroobants; M Huizing; P Aftimos; J Tol; W J G Oyen; D J Vugts; O S Hoekstra; C P Schröder; C W Menke-van der Houven van Oordt; T Guiot; A H Brouwers; A Awada; E G E de Vries; P Flamen Journal: Ann Oncol Date: 2015-11-23 Impact factor: 32.976